Disease: oropharyngeal candidiasis

Molecular Identification of Candida Species among Iranian Patients: Pursuing Candida auris

mycolabadmin

Researchers in Iran studied 136 hospital patients to identify different types of Candida fungal infections using a molecular laboratory technique called PCR-RFLP. They found that while Candida albicans remained the most common species, other Candida species were increasingly prevalent in hospitalized patients. The study developed a cost-effective diagnostic method that could help developing countries identify these fungal infections faster and more accurately, though the dangerous multidrug-resistant Candida auris was not found in their samples.

Read More »

Molecular Identification of Candida Species among Iranian Patients: Pursuing Candida auris

mycolabadmin

This study evaluated a simple molecular test called PCR-RFLP to identify different types of Candida fungi in hospitalized patients in Iran. Among 136 patient samples, researchers found eight different Candida species, with common Candida albicans being most prevalent, but other more dangerous species also present. No cases of the emerging pathogen Candida auris were found, though the test method can effectively detect it. The researchers conclude this cost-effective test could be valuable for identifying dangerous fungal infections in developing countries.

Read More »

Antifungal Potential of Streptomyces-Derived Metabolites Against Fluconazole-Resistant Oral Candida albicans: In vitro Evaluation and Mechanistic Insights

mycolabadmin

Researchers studied a type of soil bacteria called Streptomyces that produces natural compounds with strong antifungal properties. These compounds effectively killed drug-resistant Candida fungal infections that commonly affect cancer patients undergoing radiation therapy. The bacterial extract worked by damaging fungal cell membranes and blocking biofilm formation, which are protective structures the fungus uses to survive. While the results are promising for treating stubborn fungal infections, more research is needed to ensure safety for human patients.

Read More »

Abundant Yet Aberrant T Helper Cell Responses to Candida albicans Underlie Mucosal Candidiasis in Humans and Mice

mycolabadmin

Researchers studied how the immune system fights Candida albicans fungal infections. They found that a specific type of immune cell called Th17 cells is absolutely essential for controlling these infections, while other immune cells called Th2 cells actually make infections worse by blocking the protective Th17 cells. Patients with certain genetic mutations that affect how their immune system works have too many Th2 cells and not enough Th17 cells, making them vulnerable to chronic fungal infections. The study suggests that blocking a molecule called IL-4 could help restore the balance and improve patient outcomes.

Read More »

The antifungal mechanism of EntV-derived peptides is associated with a reduction in extracellular vesicle release

mycolabadmin

Researchers discovered that a small peptide derived from a bacterium called EntV can fight Candida fungal infections by targeting specialized vesicles (tiny sacs) that fungi use to spread infections. Unlike traditional antifungal drugs that kill fungi, EntV works by blocking the release of these vesicles, reducing the fungus’s ability to infect and form protective biofilms. This new approach could lead to treatments that work against drug-resistant fungi without the toxicity issues of current antifungals.

Read More »
Scroll to Top